{"Q": 1, "answer": "no", "rationale": "The segment contains 'very quickly' modifying 'respond', not a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_16060", "batch_size": 200, "batch_pos": 69, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 2, "answer": "no", "rationale": "The segment uses neutral language ('plans to launch', 'could respond very quickly') and lacks high-potency verbs, metaphors, or alert phrases.", "method": "llm_batch", "batch_id": "batch_2_10428", "batch_size": 200, "batch_pos": 54, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 3, "answer": "no", "rationale": "'plans to launch' describes a plan, not realised impact.", "method": "llm_batch", "batch_id": "batch_3_19656", "batch_size": 200, "batch_pos": 47, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a question.", "method": "llm_batch", "batch_id": "batch_4_15932", "batch_size": 200, "batch_pos": 43, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 5, "answer": "no", "rationale": "Reports plan for trial and ability to respond quickly; lacks explicit calming language about current safety.", "method": "llm_batch", "batch_id": "batch_5_5816", "batch_size": 200, "batch_pos": 42, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 6, "answer": "no", "rationale": "Segment lacks minimiser + scale contrast.", "method": "llm_batch", "batch_id": "batch_6_16460", "batch_size": 200, "batch_pos": 24, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"hop_idx": 7, "answer": "uncertain", "rationale": "Missing response from batch", "method": "fallback", "batch_id": "batch_7_15052", "batch_size": 200, "batch_pos": 21, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 7, "answer": "no", "rationale": "The segment does not contain a bare negation.", "method": "llm_batch_retry", "retry": 1, "batch_id": "batch_7_15052_r1", "batch_size": 200, "batch_pos": 21, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
{"Q": 8, "answer": "yes", "rationale": "Describes capability/preparedness: 'plans to launch a small human trial', 'could respond very quickly'.", "method": "llm_batch", "batch_id": "batch_8_17428", "batch_size": 200, "batch_pos": 164, "statement_text": "The company plans to launch a small human trial of an mRNA pandemic flu vaccine tailored to the new avian influenza subtype in the first half of 2023, he [Raffael Nachbagauer] said, adding Moderna could respond very quickly in an outbreak scenario.", "article_id": 1272}
